If you have purchased shares of Hemispherx BioPharma, Inc (NYSEAMEX:HEB) between March 19, 2012 and December 17, 2012, call 1-800-934-2921 right now to protect your rights.

Filing deadline:   02/22/2013

The shareholder lawsuit states that between the dates of March 19, 2012 and December 17, 2012 that Hemispherx BioPharma, Inc and a portion of its leaders therein made false and misleading statements regarding the product Ampligen, one of its newest medications. The officers in question are alleged to have violated the Securities Exchange Act of 1934 by issuing these types of statements between the aforementioned dates, and this complaint is filed on behalf of all persons who acquired securities of any type in Hemispherx BioPharm, Inc. Hemispherx BioPharma published their findings on March 19, 2012 regarding the drug Ampligen and the relationship between Chronic Fatigue Syndrome and the bioactivity of the medication. 

Approximately 4 months later on July 11 of the same year, the FDA and Hemispherx BioPharma announced that they had come to an agreement as to the filing requirements for BioPharma's new drug application for Chronic Fatigue Syndrom Treatment. The Ampligen medication had the complete backing of its parent company Hemispherx BioPharma, Inc. 

As a potential result of this filing with the FDA, shares in the company (NYSEAMEX:HEB) rose dramatically from a low point of $0.325 in the middle of March to a high of $1.00 by the end of September in this calendar year. 

However, a little over a week ago on December 20, the Arthritis Advisory Committee (AAC) branch of the United States FDA rejected Hemispherx BioPharma's patented drug Ampligen for use in Chronic Fatigue Syndrome. A statement from the Food and Drug administration advisory panel claimed that the proposed medicine from Hemispherx BioPharma Inc. was not ready for marketing at this time. 

Following the issuance of this advisory by the FDA, shareholders saw a decline in the price per share of Hemispherx BioPharma, Inc. (NYSEAMEX:HEB) decrease dramatically. The prices dipped from $0.64 on December 17, 2012 to $0.263 only four days later on December 21, 2012.

Own shares of Hemispherx BioPharma, Inc (NYSEAMEX:HEB)? Contact us to protect your rights.

If you have purchased shares of Hemispherx BioPharma, Inc (NYSEAMEX:HEB) between March 19, 2012 and December 17, 2012, call 1-800-934-2921 right now to protect your rights. Complete the form on this page or call attorney Bill Kyros at 1-800-934-2921 right now to protect your rights.